Amodiaquine Clearance and Its Metabolism to N-Desethylamodiaquine Is Mediated by CYP2C8: A New High Affinity and Turnover Enzyme-Specific Probe Substrate
- 1 February 2002
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 300 (2) , 399-407
- https://doi.org/10.1124/jpet.300.2.399
Abstract
Amodiaquine (AQ) metabolism to N-desethylamodiaquine (DEAQ) is the principal route of disposition in humans. Using human liver microsomes and two sets of recombinant human cytochrome P450 isoforms (from lymphoblastoids and yeast) we performed studies to identify the CYP isoform(s) involved in the metabolism of AQ. CYP2C8 was the main hepatic isoform that cleared AQ and catalyzed the formation of DEAQ. The extrahepatic P450s, 1A1 and 1B1, also cleared AQ and catalyzed the formation of an unknown metabolite M2. TheKm and Vmaxvalues for AQ N-desethylation were 1.2 μM and 2.6 pmol/min/pmol of CYP2C8 for recombinant CYP2C8, and 2.4 μM and 1462 pmol/min/mg of protein for human liver microsomes (HLMs), respectively. Relative contribution of CYP2C8 in the formation of DEAQ was estimated at 100% using the relative activity factor method. Correlation analyses between AQ metabolism and the activities of eight hepatic P450s were made on 10 different HLM samples. Both the formation of DEAQ and the clearance of AQ showed excellent correlations (r2 = 0.98 and 0.95) with 6α-hydroxylation of paclitaxel, a marker substrate for CYP2C8. The inhibition of DEAQ formation by quercetin was competitive withKi values of 1.96 for CYP2C8 and 1.56 μM for HLMs. Docking of AQ into the active site homology models of the CYP2C isoforms showed favorable interactions with CYP2C8, which supported the likelihood of an N-desethylation reaction. These data show that CYP2C8 is the main hepatic isoform responsible for the metabolism of AQ. The specificity, high affinity, and high turnover make AQ desethylation an excellent marker reaction for CYP2C8 activity.This publication has 26 references indexed in Scilit:
- Mammalian Microsomal Cytochrome P450 MonooxygenaseMolecular Cell, 2000
- Microsomal prediction of in vivo clearance of CYP2C9 substrates in humansBritish Journal of Clinical Pharmacology, 1999
- Metabolism-Dependent Neutrophil Cytotoxicity of Amodiaquine: A Comparison with Pyronaridine and Related Antimalarial DrugsChemical Research in Toxicology, 1998
- Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. CohenJournal of Molecular Biology, 1997
- Prediction of in vivo drug metabolism in the human liver from in vitro metabolism dataPharmacology & Therapeutics, 1997
- Role of hepatic metabolism in the bioactivation and detoxication of amodiaquineXenobiotica, 1995
- Utility of in vitro drug metabolism data in predicting in vivo metabolic clearanceBiochemical Pharmacology, 1994
- Amodiaquine‐induced immune agranulocytosisBritish Journal of Haematology, 1989
- Amodiaquine as a prodrug: Importance of metabolite(s) in the antimalarial effect of amodiaquine in humansLife Sciences, 1985
- A centrally acting antihypertensive agent (R28935) not mediated via central α-adrenoreceptorsEuropean Journal of Pharmacology, 1975